🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities

RecruitingNAAges 18 Years - anyAllCentre Hospitalier Universitaire, Amiens
NCT05714592 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Standard cytogenetics (CBA +/- FISH) is of diagnostic and prognostic interest in Ph- MPN. However, its value is limited by the low frequency of detected abnormalities. The development of tools to increase the sensitivity of detection of chromosomal alterations is therefore particularly adapted to these pathologies. Optical genome mapping (OGM) is a high resolution "long read" technique that allows the identification of structural and copy number variations at the whole genome level. Several recent studies suggest that OGM is a future tool for cytogenetic characterization of haematological disorders. Its ability to describe structural abnormalities, including balanced ones, represents a major advantage over currently used technologies. Thus, OGM seems to be the key tool for cytogenetics of haematological malignancies in the coming years, making it possible to replace, under certain condit

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient 18 years of age or older * Diagnosis or follow-up of polycythemia vera, essential thrombocythemia or primary or secondary myelofibrosis * Requires bone marrow cytogenetics at diagnosis or follow-up * Understanding of the French language * Information of the patient and collection of no objection * Person affiliated to a social security regime Exclusion Criteria: * Patient with BCR::ABL positive myeloproliferative neoplasia. * Person with a medical history that may impair the ability to understand the information notice
💊

What it tests

  • Blood sample
📍

Where

1 site
Centre Hospitalier Universitaire d'Amiens
Amiens, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy